Research programme: parainfluenza virus therapies - BioCryst

Drug Profile

Research programme: parainfluenza virus therapies - BioCryst

Alternative Names: BCX-2798; Parainfluenza virus hemagglutinin-neuraminidase inhibitors - BioCryst Pharmaceuticals; Parainfluenza virus HN inhibitors - BioCryst

Latest Information Update: 11 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action HN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parainfluenza virus infections

Most Recent Events

  • 07 Dec 2012 Discontinued - Preclinical for Parainfluenza virus infections in USA (PO)
  • 17 Apr 2008 Preclinical pharmacodynamics data presented at the 21st International Conference on Antiviral Research (ICAR-2008)
  • 02 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top